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PENGASINGAN DAN PENGEKSPRESAN HEMOLISIN E (HlyE)  




Analisa perbandingan proteomik Salmonella enterica serovar Typhi (S. Typhi) dan 
Salmonella enterica serovar Typhimurium (S. Typhimurium) menunjukkan 
sekumpulan protein yang diekspres unik terhadap S. Typhi. Salah satu daripada 
protein tersebut adalah hemolisin E (HlyE). Gen hlyE ini adalah spesifik untuk 
perumah manusia, tiada atau berubah fungsi dalam S. Typhimurium. Gen hlyE 
merupakan gen yang terdapat pada ‘Salmonella Pathogenecity Island (SPI) 18’. 
Dalam kajian ini, kehadiran dan fungsi gen hlyE di dalam isolat klinikal S. Typhi 
telah ditentukan. Analisis PCR dan jujukan DNA menunjukkan bahawa S. Typhi 
mempunyai keseluruhan salinan jujukan bagi gen hlyE. Walaupun gen hlyE hadir di 
dalam isolat S. Typhi, bakteria ini tidak menunjukkan zon hemolitik pada agar darah 
kuda. Peningkatan aktiviti hemolitik telah dilihat apabila S. Typhi dikultur pada agar 
darah kuda menggunakan asai cakera-difusi dengan kehadiran ampisilin. Protein 
periplasmik yang diekstrak daripada S. Typhimurium dan S. Typhi (strain vaksin dan 
isolat klinikal) menunjukkan kehadiran protein 34 kDa iaitu merupakan anggaran 
saiz untuk HlyE. Ekstrak protein periplasmik daripada S. Typhi menunjukkan aktiviti 
hemolitik yang kuat pada agar darah. Protein rekombinan HlyE menunjukkan reaksi 
positif terhadap IgG sera pesakit demam kepialu, ini menunjukkan penghasilan HlyE 
yang reaktif ketika infeksi. Protein rekombinan HlyE yang ditulenkan ini mempunyai 
kesan sitotoksik terhadap sel U937 manusia. Kajian ini memberikan informasi asas 
xv 
 
terhadap aktiviti gen hlyE dan pengetahuan tambahan dalam kajian kepatogenan S. 
Typhi terhadap manusia  
xvi 
 
ISOLATION AND EXPRESSION OF HEMOLYSIN E (HlyE)  




Comparative proteomic analysis of Salmonella enterica serovar Typhi (S. Typhi) and 
Salmonella enterica serovar Typhimurium (S. Typhimurium) revealed a subset of 
highly expressed proteins unique to S. Typhi. One of these proteins is hemolysin E 
(HlyE). The hlyE gene is necessary for human-host specificity, which is absent or 
functionally altered in S. Typhimurium. hlyE gene belongs to Salmonella 
Pathogenecity Island (SPI) 18. In this study, the presence and the function of hlyE 
gene in S. Typhi clinical isolates was determined. PCR and DNA sequence analyses 
showed that S. Typhi, serovar that is specific for human, harbors an intact copy of 
hlyE gene. Despite the presence of hlyE gene in S. Typhi isolates, the bacteria did not 
display haemolytic activity when cultured on horse blood agar plates. Increased 
haemolytic activity was observed when S. Typhi was grown on horse agar plates in 
disk-diffusion assay in the presence of ampicillin disk. Crude periplasmic proteins 
extracted from S. Typhimurium and S.Typhi (vaccine strain and clinical isolates) 
showed the presence of 34 kDa proteins, which is an expected size for HlyE. The 
crude protein extracts from S. Typhi showed strong haemolytic activity on the blood 
agar plates. HlyE recombinant protein showed positive reaction against IgG of sera 
from typhoid patients, suggesting reactive HlyE production during infection. The 
purified HlyE recombinant proteins have a cytotoxic activity towards U937 human 
monocytic cell line. This research provides fundamental information on the activity 
xvii 
 
of hlyE gene product and contributes additional knowledge in the study of S. Typhi 









1.1 Salmonella and disease: An overview 
‘Salmonella’ was named after Daniel Elmer Salmon, an American veterinary 
pathologist, who discovered Salmonella bacterium isolated from pigs in 1885. 
Currently, there are 2579 classified serovars of Salmonella enterica (Grimont & 
Patrick, 2007) which are differentiated by their antigenic characteristics and host 
range (Grimont & Patrick, 2007; Popoff & Minor, 1997). The nomenclature system 
used for the genus Salmonella is based on recommendations from the Centers for 
Disease Control and Prevention (CDC), USA (Brenner et al., 2000). The complete 
names of these serovars are commonly abbreviated such as ‘Salmonella enterica 
serovar Typhi’ is commonly referred as Salmonella Typhi or S. Typhi (Judicial, 
2005). The various Salmonella enterica serovars infect a wide range of vertebrate 
animals. Several serovars have very narrow and restricted host. For example, humans 
are host-specific for serovar Typhi whereas serovar Pullorum exclusively infects 
chicken. These host-specific serovars cause a systemic illness that could be fatal if 
left untreated. In contrast to S. Typhi, S. Typhimurium, infects a wide range of hosts 
including humans and other vertebrates. 
 
Infections of S. enterica in human may display different clinical manifestation 
depending on the Salmonella enterica serovars. There are two main clinical 
manifestation associated with Salmonella infections in humans. First, S. Typhi and S. 
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Paratyphi cause systemic infection called typhoid fever. This enteric fever is a life-
threatening disease and display several symptoms like prolonged fever (38°C and 
above) followed by malaise, anorexia and nausea. 1‒3% of hospitalized patients 
faced the more serious complication, which is intestinal perforation. After traversing 
the intestinal mucosa, the causative bacteria then disseminate, resulting in secondary 
infections of the liver, spleen, bone narrow, gallbladder and Peyer’s patches of the 
terminal ileum (Parry et al., 2002). The second is gastrointestinal disease, the more 
common clinical outcome of Salmonella infection in humans caused by non-
typhoidal Salmonella. This non-typhoidal salmonellosis is commonly caused by S. 
Typhimurium and S. Enteritidis, which results in self-limiting disease such as nausea, 
vomiting, abdominal cramping and diarrhea. The non-typhoidal Salmonella are 
primarily transmitted to human directly or indirectly from animal sources and mostly 
via foodborne. In some cases the sources of this infection are pets, direct personal 
contact, nosocomial infection, waterborne and contaminated drugs and solutions 
(Hohman, 2001; Ohl & Miller, 2001). Patients less than 3 months old, greater than 
50 years old, and patients with diabetes, malignancy, rheumatologic disorders, HIV 
infection and immunosuppression, are at risk of getting gastrointestinal 
salmonellosis. About 5% of non-typhoidal infections are associated with bacteremia 
(Hohman, 2001; Pang et al., 1995). 
 
1.2 Typhoid fever  
Typhoid fever is a global health problem. According to World Health Organization 
(WHO), approximately 216 000 to 600 000 (1-4%) deaths are reported yearly from 
21 million registered typhoid cases worldwide. It is estimated that 90% of the death 
cases occur in Asia. Ministry of Health (MOH) Malaysia reported that the annual 
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incidences of typhoid in Malaysia for the past 10 years (1998‒2007) is below 5 cases 
per 100 000 population, which is classified as low endemic region for typhoid fever. 
Kelantan has the highest annual incidence when compared to other states in Malaysia. 
From April to June 2005, an outbreak occurred in Kelantan with 735 reported cases 
and 2 deaths (MOH, 2007). 
  
A person is confirmed to have typhoid fever when he has a fever (38°C and above) 
for at least 3 days with a laboratory confirmed positive culture (blood, bone marrow 
or stool) for S. Typhi (WHO, 2003). Mode of infection is by ingestion of food or 
water contaminated with fecal that contains S. Typhi. The infection is transmitted 
from person to person through poor hygiene practices and sewage contamination of 
water supply (MOH, 2007). Acute systemic illness is characterized by prolonged 
fever, abdominal pain, and persistent bacteremia. About 10 to 20% of patients 
showed acute diarrhea symptom after ingestion of S. Typhi. This may last for several 
days. On the second week of infection, the fever continues and the patient may 
appear severely ill. Gastrointestinal complications, such as bleeding or perforation 
may occur at any time but usually during the third week of infection (Levine, 2009). 
Common physical symptoms for typhoid patients are prolonged fever, brown coated 
tongue, confusion, decreased auditory acuity and nuchal rigidity (Crum, 2003). Rose 
spots on abdomen and chest may develop on some patients (Levine, 2009). 
 
1.3 Salmonella enterica serovar Typhi 
S. Typhi is a rod-shape, Gram negative, facultative anaerobic, non-encapsulated, 
flagellated bacilli belonging to the family of Enterobacteriaceae. It is motile with 
peritrichous flagella. S. Typhi is identified in the laboratory by culturing on selective 
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media followed by several biochemical and serological tests. Suspected colony 
obtained from selective media is further distinguished from other Salmonella 
serotypes by its biochemical properties and agglutination with specific antisera. For 
example, on Salmonella Shigella (SS) agar, Salmonellae produce lactose non-
fermenting colonies with black centres. The colony with such appearance was chosen 
for biochemical tests screening as described in Table 1.1. In serological test, S. Typhi 
is positive for LPS antigen O9 and O12, protein flagella antigen H-d and 




Table 1.1: Biochemical tests for differentiation of S. Typhi from related 
subspecies (adapted from WHO, 2003) 
 
Organism 
Kliger’s Iron Agar Test Motility, Indole, Urea Tests Citrate 
Test Slant Butt H2S Gas Motility Indole Urea 
S. Typhi Alkaline Acid Wk+ - + - - - 
S. Paratyphi A Alkaline Acid - + + - - - 
Other 
Salmonella sp. 
Alkaline Acid V V + - - V 
 
‘+’ = Positive 
‘-‘ = Negative 
Wk + = Weak positive 
V = Variable result 





1.4 Laboratory diagnosis of typhoid fever 
1.4.1 Identification of S. Typhi by culture method 
The definitive diagnosis of typhoid fever depends on the isolation of S. Typhi from 
blood, bone marrow or a specific anatomical lesion from typhoid patients. Bone 
marrow aspirate culture is the gold standard for the diagnosis of typhoid fever and is 
principally important for patients who have been previously treated, have a long 
history of illness and have been getting negative for blood culture at the 
recommended volume of blood (WHO, 2003). However, bone marrow aspirate 
samples are difficult to obtain and relatively (Bhutta, 2006). Thus, blood culture is 
the best option to diagnose typhoid fever, as more than 80% of typhoid patients have 
the causative bacteria in their blood (WHO, 2003). 
 
1.4.2 Serological diagnostic methods 
Serological diagnostic tests give a rapid diagnosis of typhoid fever compared to 
bacterial culture method, which requires 3 to 5 days to perform. There are several 
serological methods widely being used to diagnose typhoid fever. Felix-Widal test 
works by detecting agglutinating antibodies against O and H antigens. However, the 
test only gives moderate sensitivity and specificity. It produces false negative results 
for up to 30% of culture-positive cases of typhoid fever (WHO, 2003). Moreover, 
other Salmonella serotypes also posses the same O and H antigens similar to S. Typhi 
(WHO, 2003; Grimont & Patrick, 2007) and there are cross-reacting epitopes 
between S. Typhi with other Enterobacteriaceae (WHO, 2003). These factors can 
lead to false positive results. However, the test is still being used  in many areas since 




TYPHIDOT® test kit is developed under USM license based on the principle of dot-
blot enzyme immune-assay (Dot-EIA), for detecting IgM and IgG antibodies specific 
for a 50 kDa antigen of S. Typhi (Ismail et al., 1991a). This protein is an outer 
membrane protein and is found to be a specific protein to S. Typhi (Ismail et al., 
1991b). Dot EIA test offers simplicity, speedity/rapidity, specificity (75%), 
sensitivity (95%) and cost-effective (Choo et al., 1994). However, in convalescence 
or reinfection cases, the level of IgG is boosted by the secondary immune response, 
which mask the IgM. In order to increase the diagnostic accuracy, TYPHIDOT-M 
was later developed where the original TYPHIDOT® test was modified by 
inactivating total IgG in the sera sample. Inactivation of IgG removes competitive 
binding and allows access of the antigen to bind to the specific IgM (Bhutta & 
Mansurali, 1999). This test was reported to be useful in typhoid endemic areas, since 
it can be differentiate between convalescence and acute cases. This test was reported 
to have 92% sensitivity and 100% specificity in independent evaluation studies for 
all age groups of typhoid fever (Bhutta, 2006). 
 
1.5 Pathogenicity of S. Typhi 
Once the S. Typhi enters the host via ingestion of contaminated food or water, it 
passes through the stomach and the gastric acid barrier, then it reaches a site where it 
can invade the small intestine epithelial cells. S. Typhi invades the epithelium 
through two ways, which are by invasion of microfold (M) cells of Peyer’s patches 
and by direct translocation across the absorptive epithelial cells. After penetration 
into the intestinal mucosa, the bacteria are immediately engulfed by macrophages but 
resist from being killed. Through these vehicles, they are able to enter mesenteric 
lymph nodes. The bacteria multiply until the critical microbial load is sufficient to 
